JP Morgan Chase
TCRX icon

JP Morgan Chase’s TScan Therapeutics TCRX Stock Holding History

JP Morgan Chase’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5K Sell
16,436
-16,913
-51% -$18.1K ﹤0.01% 6627
2025
Q4 		$33.3K Sell
33,349
-204,401
-86% -$296K ﹤0.01% 6375
2025
Q3 		$433K Sell
237,750
-49,993
-17% -$88.6K ﹤0.01% 5118
2025
Q2 		$417K Buy
287,743
+22,642
+9% +$32.7K ﹤0.01% 4871
2025
Q1 		$366K Buy
265,101
+198,345
+297% +$429K ﹤0.01% 4959
2024
Q4 		$203K Buy
66,756
+34,951
+110% +$158K ﹤0.01% 5467
2024
Q3 		$158K Buy
31,805
+15,441
+94% +$93.2K ﹤0.01% 5511
2024
Q2 		$95.7K Sell
16,364
-50,649
-76% -$399K ﹤0.01% 5537
2024
Q1 		$532K Buy
67,013
+33,783
+102% +$213K ﹤0.01% 4750
2023
Q4 		$194K Buy
+33,230
New +$152K ﹤0.01% 5404
2022
Q2 		– Sell
-361
Closed -$1K – 6882
2022
Q1 		$1K Buy
+361
New +$1.56K ﹤0.01% 6501

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

JP Morgan Chase's TCRX Position: Q1 2026 in Review

JP Morgan Chase reduced its TScan Therapeutics (TCRX) stake by 51% in Q1 2026, selling an estimated $18.1K and leaving 16,436 shares worth $15.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6627.

JP Morgan Chase first reported a position in TCRX in Q1 2022 and has held it in 11 quarters since. The position peaked at $532K in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • JP Morgan Chase held 16,436 shares of TScan Therapeutics worth $15.5K as of Q1 2026.
  • JP Morgan Chase sold 16,913 TScan Therapeutics shares in Q1 2026, an estimated $18.1K.
  • TScan Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6627 holding.
  • JP Morgan Chase first reported a position in TScan Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • JP Morgan Chase's TScan Therapeutics position peaked at $532K in Q1 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.